# Ursula A. Matulonis

Source: https://onco.cc/people/ursula-matulonis/  
OnCo record `ursula-matulonis` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ursula Matulonis led the MIRASOL trial that gave ovarian cancer its first ADC with a survival benefit.

## Summary

Ursula A. Matulonis is Chief of the Division of Gynecologic Oncology at Dana-Farber Brigham Cancer Center. She is a gynaecologic oncologist known for leading the MIRASOL trial of mirvetuximab soravtansine, which gave ovarian cancer its first antibody-drug conjugate, as well as trials of PARP inhibitors and bevacizumab combinations. Her selected paper reports mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancer. She continues to lead trials of PARP inhibitors such as olaparib and of ADCs in ovarian cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief, Division of Gynecologic Oncology
- Specialisms: Ovarian cancer; PARP inhibitors; Antibody-drug conjugates

## Sources

- Dana-Farber profile: https://www.dana-farber.org/find-a-doctor/ursula-a-matulonis
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Matulonis%20UA%5BAuthor%5D

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [Folate receptor alpha](https://onco.cc/targets/folr1/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Mirvetuximab soravtansine](https://onco.cc/drugs/mirvetuximab-soravtansine/), [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/), [Society of Gynecologic Oncology](https://onco.cc/institutions/sgo/)
- trials: [MIRASOL / GOG-3045](https://onco.cc/trials/mirasol/), [SORAYA](https://onco.cc/trials/soraya/)

---
JSON: https://onco.cc/api/v1/entities/ursula-matulonis.json